Mescaline vs Psilocybin
Mescaline comes from certain cacti and psilocybin from fungi. A direct trial compared them with LSD in healthy adults. Here is what differs, what is similar, and what is unknown.
Content last updated . This page has not been medically reviewed.
Urgent first. For a medical emergency or suspected poisoning, call 911 or US Poison Help at 1-800-222-1222. In the US, call or text 988 for a mental health crisis.
This page is education only. It gives no amounts, no equivalence between mescaline and psilocybin, and no information on finding, preparing or identifying cacti or fungi.
Different origins and chemistry
Mescaline (3,4,5-trimethoxyphenethylamine) is a naturally occurring alkaloid found in cacti, mainly the peyote cactus (Lophophora williamsii) and cacti of the genus Echinopsis. [1] NIDA notes it can also be lab-made. [2] Psilocybin is a compound from certain mushrooms. [2] Psilocybin is a tryptamine and a prodrug that the body turns into psilocin. [3][4] Mescaline is a phenethylamine derivative with signs consistent with a sympathomimetic effect, and it is largely excreted unchanged in human urine. [5][6]Both are described as acting mainly at the serotonin 5-HT2A receptor. [6][4] This is one shared feature, not proof that effects are identical.
The direct comparison
Evidence level: one randomized, double-blind, placebo-controlled crossover trial in 32 healthy participants, comparing mescaline, LSD and psilocybin. [7]| Finding | Result |
|---|---|
| Subjective effects | Comparable across several rating scales at the higher mescaline study amount, with no qualitative differences found [7] |
| Duration | Mean 11.1 h for mescaline, 8.2 h for LSD, 4.9 h for psilocybin at the amounts studied [7] |
| Blood pressure and heart rate | Moderate for all; psilocybin raised diastolic blood pressure more than LSD [7] |
| Tolerability | Comparable, but mescaline caused slightly more adverse effects 12-24 hours later [7] |
Limits: healthy adults, a controlled setting, study-specific amounts, short follow-up. The durations belong to those amounts and do not apply to any cactus or mushroom product.
Treatment evidence
Evidence labels: promising but limited (psilocybin in depression), insufficient evidence (mescaline).NIDA reports Breakthrough Therapy designation by FDA for two psilocybin formulations being studied for depression, which is not an approval. [2] For mescaline, a review concluded that its ability to help overcome alcoholism and improve mental well-being makes it potentially beneficial, but that is a reviewers' conclusion; we found no modern controlled trials of mescaline for these uses in the sources read. [1] Reviewers also note research on mescaline has been limited since the early 1970s. [1]
Risks
For mescaline, a toxicology review found most intoxications mild, addiction and dependence practically absent, and exposure rarely confirmed by testing. [5] For psilocybin, a meta-analysis of therapeutic-dose trials found headache, nausea, anxiety, dizziness and raised blood pressure more common than with comparators. [8] Across classic psychedelics, serious adverse events were reported in about 4% of participants with pre-existing neuropsychiatric disorders and none in healthy participants. [9] Safety in pregnancy is unknown for both; NIDA says there are no safety data for psilocybin in pregnancy. [2]Culture and conservation
Peyote has a long history of use: archaeological evidence dates back more than 5,000 years. [10] Peyote has also been described as threatened, and the Native American Church context matters. [11] See peyote conservation and peyote and its traditional contexts. Psilocybin is not a substitute for a tradition either.Legal status
Not legal advice; laws change. In the United States, 21 CFR 1308.11 lists mescaline, peyote and psilocybin in Schedule I (eCFR, read 2026-10-22). [12] A separate rule says the peyote listing does not apply to the nondrug use of peyote in bona fide Native American Church religious ceremonies. [13] Other countries: not verified. See psychedelic legal status by country.No winner
For each alone see mescaline and psilocybin.Frequently asked questions
Is mescaline a mushroom compound?
No. It is found in cacti such as peyote and Echinopsis. Psilocybin is from fungi. [1][2]
Which lasts longer?
In one trial in healthy adults, mescaline lasted longer than LSD and psilocybin at the amounts studied. [7]
Is one safer?
No safety ranking is possible. Tolerability was comparable in the trial, but data for mescaline are limited. [7]
Have they been tested as treatments?
Psilocybin has been tested more. Mescaline: insufficient evidence in the sources read. [1]
References
- Vamvakopoulou IA et al. Mescaline: The forgotten psychedelic. Neuropharmacology. 2023;222:109294. Read 2026-10-22 (abstract on PubMed).
- National Institute on Drug Abuse, Psychedelic and Dissociative Drugs. Read 2026-10-22.
- Gotvaldova K et al. Stability of psilocybin and its four analogs in the biomass of the psychotropic mushroom Psilocybe cubensis. Drug Test Anal. 2021;13(2):439-446. Read 2026-10-22 (abstract on PubMed).
- Dinis-Oliveira RJ. Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. Drug Metab Rev. 2017;49(1):84-91. Read 2026-10-22 (abstract on PubMed).
- Dinis-Oliveira RJ et al. Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions. Curr Mol Pharmacol. 2019;12(3):184-194. Read 2026-10-22 (abstract on PubMed).
- Cassels BK, Saez-Briones P. Dark Classics in Chemical Neuroscience: Mescaline. ACS Chem Neurosci. 2018;9(10):2448-2458. Read 2026-10-22 (abstract on PubMed).
- Ley L et al. Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants. Neuropsychopharmacology. 2023;48(11):1659-1667. Read 2026-10-22 (abstract on PubMed).
- Yerubandi A et al. Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2024;7(4):e245960. Read 2026-10-22 (abstract on PubMed).
- Hinkle JT et al. Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2024;81(12):1225-1235. Read 2026-10-22 (abstract on PubMed).
- Carod-Artal FJ. Hallucinogenic drugs in pre-Columbian Mesoamerican cultures. Neurologia. 2015;30(1):42-49. Read 2026-10-22 (abstract on PubMed).
- Iron Rope S, Smith R, Moore S, Sacred Peyote Conservation: Respecting Indigenous Traditions, MAPS Bulletin Spring 2020. Read 2026-10-22.
- US Electronic Code of Federal Regulations, 21 CFR 1308.11 Schedule I. Read 2026-10-22.
- US Electronic Code of Federal Regulations, 21 CFR 1307.31 Native American Church. Read 2026-10-22.